Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by BidaskClub

BidaskClub lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a research report released on Saturday morning, BidAskClub reports.

A number of other analysts have also recently issued reports on the company. Cantor Fitzgerald upped their target price on Aurinia Pharmaceuticals from $24.00 to $30.00 in a research report on Thursday, December 5th. Jefferies Financial Group began coverage on Aurinia Pharmaceuticals in a research report on Friday, January 10th. They issued a buy rating and a $27.00 target price for the company. Zacks Investment Research raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, November 28th. Royal Bank of Canada upped their target price on Aurinia Pharmaceuticals from $11.00 to $20.00 and gave the company an outperform rating in a research report on Thursday, December 5th. Finally, HC Wainwright upped their target price on Aurinia Pharmaceuticals from $25.00 to $32.00 and gave the company a buy rating in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $20.41.

AUPH opened at $19.91 on Friday. Aurinia Pharmaceuticals has a one year low of $3.52 and a one year high of $21.93. The company has a market cap of $2.16 billion, a P/E ratio of -26.20 and a beta of 1.68. The business’s 50-day simple moving average is $17.34 and its 200-day simple moving average is $8.62.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, November 14th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.05 million. Analysts forecast that Aurinia Pharmaceuticals will post -0.73 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in AUPH. Tower Research Capital LLC TRC lifted its position in Aurinia Pharmaceuticals by 630.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,382 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 7,234 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in Aurinia Pharmaceuticals by 42.9% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 3,000 shares during the period. Toronto Dominion Bank lifted its position in Aurinia Pharmaceuticals by 26.3% during the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,575 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $88,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Aurinia Pharmaceuticals by 29.0% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,150 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 4,300 shares during the period. 28.23% of the stock is owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Trade War

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.